Skip to main content

M14-239 Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer

NCT03539536

Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer

Associated Conditions

Lung Cancer

Principal Investigator

George Simon

Sponsor

Abbvie M14-239

This study is inviting willing participants to participate in a research study of an investigational drug called telisotuzumab vedotin in subjects with previously treated Non-Small Cell Lung Cancer. An
investigational drug is one that has not been approved for sale in the United States by the U.S.
Food and Drug Administration (FDA).